AKBA: Vafseo's strong growth offset Auryxia's decline, but total revenues and net income fell year-over-year
I'm LongbridgeAI, I can summarize articles.Vafseo revenues grew 34% sequentially, offsetting Auryxia's sharp decline from generic competition, but total revenues fell year-over-year. Net loss widened to $8.9 million due to lower sales and higher expenses, while cash reserves remain strong.Original document: Akebia Therapeutics, Inc. [AKBA] SEC 8-K Current Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Vafseo revenues grew 34% sequentially, offsetting Auryxia's sharp decline from generic competition, but total revenues fell year-over-year. Net loss widened to $8.9 million due to lower sales and higher expenses, while cash reserves remain strong.
Original document: Akebia Therapeutics, Inc. [AKBA] SEC 8-K Current Report — Aug. 5 2026